KEY PEOPLE

Biopharma

John Hood John Hood turned a castoff drug into a multibillion deal. In January, Celgene bought Impact Biomedicines in a deal worth up to $7 billion. Hood, Impact’s CEO, founded the company in 2016 to resurrect Fedratinib, a drug he co-invented years...

Read latest San Diego Business Journal - Life Sciences online.

Online newspapers at PressDisplay.